Incorporated in December 2001, Innovax is a dedicated R&D centre wholly-owned by CCM with core activities in carrying out research and development in pharmaceutical products. It provides scientific and technical knowledge and skill in the development of high quality, safe and efficacious pharmaceutical products in the pre and post-registration drug development stage.
Innovax has 3 main laboratories located in a 63,000 sq. ft. 3-storey detached R&D building.
It has a Formulation R&D Department that specializes in developing pharmaceutical products which include nutraceutical, herbal and OTC. The Analytical Department specializes in pharmaceutical chemistry analysis of raw materials and finished products. Other departments include Regulatory Affairs, Quality Assurance and Pipeline which are vital to the day-to-day R&D activities.
Innovax has the special technology for all types of dosage forms with niche technologies in:-
- Immediate Release technology
- Slow-release and modified release technology
- Palletisation technology
The R&D Centre is run by a group of scientists with wide experience in pharmaceutical technology, chemistry, clinical pharmacology, microbiology and biotechnology.
Innovax have produced more than 5 slow release products namely Zolterol SR (for pain relief), Carinox (for upper respiratory tract infection symptom), Imdex (Isosorbide-5-Mononitrate Controlled-Release) and others.
It won the special MITI Industry Excellence Award for Best Innovative Product for Omesec in 2004. Omesec is used for the treatment of peptic ulcer disease developed by using mini tab technology.
It has also obtained its ISO 17025 certification for several analytical testing.
Innovax implemented a 'Good Pharmaceutical Pipeline Product Practice' (GP4) in 2008 and will expect tremendous improvement in the product pipeline in the near future.
It has ambitious plans to go regionally and globally in outsourcing and partnering and also involve in collaborative research involving the sharing of IP.